NEWAMSTERDAM PHARMA CO NV-27 (NAMSW) Stock News

NASDAQ:NAMSW - Nasdaq - - Currency: USD

12 +1.34 (+12.57%)

Technical Analysis

NAMSW Latest News, Press Relases and Analysis

All

Press Releases

15 hours ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

15 hours ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

8 days ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025

8 days ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025

16 days ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025

2 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial

2 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial

2 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma to Host R&D Day on June 11, 2025

2 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

2 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

3 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference

3 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

3 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

3 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

3 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

3 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

3 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

4 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

4 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

4 months ago - By: Yahoo Finance - Mentions: RIVN NAMS AMZN

Nissan sells its Indian plant to Renault to raise cash

4 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

4 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

5 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

5 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

5 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

5 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

6 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference

6 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference

7 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities

7 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

7 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

8 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

8 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

8 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

8 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

8 months ago - By: NewAmsterdam Pharma N.V. - Mentions: NAMS

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants